Schematic showing the novel mechanism by which PTGES3 nuclear transcriptional regulation promotes hepatocellular carcinoma proliferation and immunosuppression. Credit: Wang Nianfei
A research team led by Prof. Wang Hongzhi at the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has found a novel role of prostaglandin E synthase 3 (PTGES3) in liver cancer, revealing how it drives both tumor growth and immune suppression.
The study was published in Molecular Biomedicine.
Hepatocellular carcinoma (HCC) is a highly lethal liver cancer with limited treatment outcomes. Understanding the key regulators of tumor progression and immune suppression is important for improving therapy.
In this study, PTGES3, a cytoplasmic co-chaperone of HSP90, was identified as a nuclear transcriptional regulator. It was significantly overexpressed in HCC and was associated with poor patient outcomes.
